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ABSTRACT
Patients with inherited metabolic storage disorders are at a higher risk of developing pulmonary complications
after hematopoietic cell transplantation (HCT). This single-center prospective study of 48 consecutive inher-
ited metabolic storage disorder patients was performed to identify risk factors for the development of
pulmonary complications after HCT. Before HCT, subjects underwent bronchoalveolar lavage (BAL) for cell
count, culture, nitrite levels, and analysis of proinflammatory cytokines and chemokines. The overall incidence
of pulmonary complications was 52% (infectious, 23%; noninfectious, 29%) over a period of 4 years. Diffuse
alveolar hemorrhage was the most frequent noninfectious complication and occurred in 19% of patients, all of
whom had a diagnosis of mucopolysaccharidosis (Hurler and Maroteaux-Lamy syndromes). Levels of inter-
leukin (IL)–1, IL-6, IL-8, tumor necrosis factor , macrophage inflammatory protein 1, and granulocyte
colony-stimulating factor in BAL fluid samples obtained before HCT were higher in patients with mucopo-
lysaccharidoses than in patients with leukodystrophies. In addition, levels of IL-1, IL-6, IL-8, and granulocyte
colony-stimulating factor were increased in the BAL fluid of patients who developed noninfectious pulmonary
complications compared with those who did not develop pulmonary complications. It is interesting to note that
most noninfectious pulmonary complications occurred in patients with mucopolysaccharidoses, especially
diffuse alveolar hemorrhage, which occurred exclusively in patients with mucopolysaccharidoses. Higher levels
of bronchial proinflammatory cytokines and chemokines may be predictive of the development of subsequent
posttransplantation noninfectious complications in patients with mucopolysaccharidoses, especially those with
Hurler syndrome. Larger studies will be required to further elucidate etiologic mechanisms and predictive factors.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT)
as been used as effective therapy for some inherited
etabolic storage disorders (IMSDs) for the past 2
ecades [1]. IMSDs that can be effectively treated by [
30CT include the mucopolysaccharidoses (MPS), such
s Hurler [2-4] and Maroteaux-Lamy [5] syndromes;
eukodystrophies, such as cerebral X-linked adreno-
eukodystrophy [6-8]; metachromatic leukodystrophy
9,10]; globoid cell leukodystrophy [11]; and glycop-
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Botein metabolism disorders, such as  mannosidosis
12,13] and mucolipidosis II (I-cell disease) [14].
The success of HCT in treating IMSDs is limited
articularly by a high incidence, approaching 33%, of
osttransplantation pulmonary complications [15,16].
t the University of Minnesota, 233 patients with
MSDs have undergone HCT over 21 years. Review
f our data revealed a 16% incidence of diffuse alve-
lar hemorrhage (DAH) in patients with Hurler syn-
rome [17]. A recent report found a 20% incidence (3
f 15 patients) of DAH in patients with Hurler syn-
rome [18]. The incidence of DAH in both allogeneic
nd autologous HCT recipients has been reported to
e 5% [19,20], whereas that of idiopathic pneumonia
yndrome (IPS) has been 8%-12% [21,22], in both
dult and pediatric patients.
Although the pathophysiology of DAH is not well
nderstood, IPS has been studied by many investiga-
ors in murine models of bone marrow transplanta-
ion. DAH that occurs as a complication of autoim-
une diseases has been thought to be secondary to
mall vessel vasculitis [23]. Shankar et al. [24] de-
cribed DAH as an early complication of HCT when
he cytokine milieu in the lung parenchyma is antiﬁ-
rotic. Proinﬂammatory cytokines including interleu-
in (IL)–6, tumor necrosis factor (TNF)–, and in-
erferon  have been found to play a critical role in the
evelopment of IPS in murine models of HCT. In
ddition to cytokines, chemokine levels such as mono-
yte chemotactic protein (MCP, or CCL2), macro-
hage inﬂammatory protein (MIP)–1 (or CCL3),
nd RANTES (regulated upon activation normal T
ells expressed and secreted, or CCL5) have been
ound to be increased in the lungs of mice that devel-
ped IPS in an allogeneic HCT system [25,26]. More-
ver, early after HCT, nitric oxide (NO), superoxide,
nd their derived reactive species have been shown to
lay important roles in inﬂammatory and oxidant re-
ponses that lead to IPS-related injury and death,
robably via activation of proinﬂammatory cytokines
uch as TNF- and interferon  [27,28]. Compared
ith serum, bronchoalveolar lavage (BAL) allows di-
ect sampling of the alveolar space. It is a useful
iagnostic tool in evaluating HCT-related pulmonary
omplications [29]. In a recent study, increased levels
f TNF- and reduced levels of IL-18 in BAL ﬂuid
ere found in patients with pulmonary complications
fter HCT [30].
Thus, the immune system—in particular, a com-
lex interaction between proinﬂammatory cytokines
nd chemokines—seems to play a critical role in the
evelopment of pulmonary complications after HCT.
t is unclear whether the cytokine response is exag-
erated in patients with IMSDs, especially those with
PS (Hurler and Maroteaux-Lamy), to account for
heir increased risk of pulmonary complications, par-
icularly DAH. We hypothesized that increased levels m
B&MTf proinﬂammatory cytokines and NO production
ithin the lung before HCT would be correlated with
he development of signiﬁcant pulmonary complica-
ions after HCT. This article describes a prospective
tudy that analyzed BAL ﬂuid before HCT to deter-
ine whether cytokine abnormalities were more likely
o be present in patients who developed pulmonary
omplications after HCT.
ATERIALS AND METHODS
atients
Between August 1999 and March 2003, 48 con-
ecutive patients with IMSDs were enrolled in this
rospective study. The study protocol was approved
y the Human Subjects Committee at the University
f Minnesota, and informed consent was obtained
rom the subject or a parent or legal guardian. Twenty-
hree patients had a diagnosis of MPS (ie, Hurler or
aroteaux-Lamy syndrome), and the remaining 25
ad primary genetic diseases other than MPS, includ-
ng X-linked adrenoleukodystrophy, metachromatic
eukodystrophy, globoid cell leukodystrophy, I-cell
isease, and -mannosidosis. Patient characteristics
re shown in Table 1.
re-HCT BAL Fluid Analysis
Patients underwent ﬁberoptic bronchoscopy and
AL before HCT, and these were performed during
ther necessary pre-HCT procedures that required
eneral anesthesia (eg, placement of a central venous
atheter). The bronchoscope was advanced into the
ndotracheal tube and directed to either the lingula or
he right middle lobe. The bronchoscope was wedged
nto a segmental or subsegmental airway, and 3 se-
uential aliquots of 1 mL/kg sterile, preservative-free
ormal saline were instilled and immediately with-
rawn by gentle suction. Typically, 33% to 50% of the
otal amount of ﬂuid instilled was recovered. BAL ﬂuid
as analyzed for cell count, differential, microbiology,
otal protein, cytokine levels, and nitrite levels. Microbi-
logic studies included bacterial, mycobacterial, fungal,
nd viral cultures. Cell count with differential and cul-
ures were performed by using conventional techniques
n the clinical laboratory. Nitrite in BAL ﬂuid was
easured according to the Greiss method after con-
ersion of nitrate to nitrite with the reduced nicotin-
mide adenine dinucleotide–dependent enzyme ni-
rate reductase (Calbiochem, La Jolla, CA). BAL ﬂuid
otal protein was determined by the bicinchoninic acid
Sigma, St. Louis, MO) method with bovine serum
lbumin as the standard. BAL samples were centri-
uged to remove cells and debris, and the ﬂuid was
tored at 80°C until cytokine or chemokine analysis.
CP-1 (CCL2) and MIP-1 (CCL3) were deter-
ined by using commercial enzyme-linked immu-
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4osorbent assay methods (R&D Systems, Minneapo-
is, MN). BAL ﬂuid was also assayed by the Luminex
ethod (Austin, TX) by using human-speciﬁc bead
ets (R&D Systems) that included IL-1, IL-2, IL-4,
L-6, IL-8, IL-10, and TNF-. For the cytokine anal-
ses, all specimens were assayed in duplicate, and
esults were averaged.
ulmonary Complications
Pulmonary complications were categorized de-
ending on the clinical, radiographic, and broncho-
copic ﬁndings. Patients whose BAL or lung biopsy
esults were positive for speciﬁc pathogens and who
ad radiographic ﬁndings suggestive of infection were
onsidered to have developed an infectious pulmonary
omplication. Patients whose BAL or lung biopsy re-
ults were negative for speciﬁc pathogens and who had
bnormal radiographic ﬁndings consistent with IPS or
AH were considered to have developed a noninfec-
ious pulmonary complication. Patients were moni-
ored weekly for the development of infectious and
oninfectious pulmonary complications through day
00 after transplantation, and then monitoring con-
inued at days 180 and 270 and 1 year. The method of
onitoring was chosen according to the standard in-
titutional practice, which included investigating any
ebrile episode lasting more than 72 hours without
n identiﬁable source by obtaining computed tomo-
raphic scans of chest and investigating further by
ronchoscopy or lung biopsy in case of positive radio-
raphic ﬁndings. All patients in the infectious compli-
able 1. Patient Characteristics
Characteristics
MPS I
(n  21)
MPS VI
(n  2)
edian age at HCT, y (range) 1.5 (0.8-2.8) 6.2 (4.6-7.8
ex
Male 12 1
Female 9 1
tem cell source
Unrelated bone marrow 10 1
Unrelated cord blood 6 1
Related bone marrow 5 0
LA match
6/6 12 1
5/6 7 1
4/6 2 0
onditioning regimen
Bu/Cy 18 2
Cy/TBI 0 0
Other 3 0
VHD prophylaxis
CSA  prednisone 4 1
T-cell depletion 12 1
CSA  other 5 0
PS I indicates Hurler syndrome; MPS VI, Maroteaux-Lamy synd
cell leukodystrophy; MLD, metachromatic leukodystrophy; I-C
cyclophosphamide/total body irradiation; other, busulfan, ﬂudaations group had clinical and/or radiologic evidence i
32f pulmonary involvement, and a speciﬁc infectious
rganism was identiﬁed. All pulmonary events were
eviewed by study investigators (S.K. and K.S.B) and
lassiﬁed as either infectious or noninfectious on the
asis of all clinical, radiologic, and laboratory data
vailable. Within the noninfectious group, DAH was
eﬁned as active pulmonary hemorrhage, as evidenced
y bloody return of the lavage ﬂuid obtained during
ronchoscopic evaluation or the presence of blood in
he lower airway upon endotracheal intubation, an
bsence of pulmonary infections, a requirement for
entilatory support, and a chest radiograph showing a
iffuse alveolar pattern. IPS was deﬁned as diffuse
ung injury occurring after HCT for which an infec-
ious etiology was not identiﬁed [21]. The diagnosis of
ulmonary cytolytic thrombi was made on the basis of
ulmonary nodules with conﬁrmed histology on lung
iopsy specimens [31]. Similarly, the diagnosis of
osttransplantation lymphoproliferative disease with
ulmonary involvement was made by open lung bi-
psy. Pulmonary hypertension was diagnosed in 1
atient by chest imaging and echocardiographic ﬁnd-
ngs and ultimately conﬁrmed histologically. The
ause of death was deﬁned as the primary event that
ed to death in the absence of other underlying con-
ributing factors.
tatistical Analysis
To account for variations in the volume of BAL
uid collected during the bronchoscopy for each sub-
ect, all cytokine and chemokine levels were standard-
Mann
n  1)
ALD
(n  16)
MLD
(n  6)
GLD
(n  1)
I-Cell
(n  1)
4.1 9.3 (4.0-16) 8.1 (4.0-40) 3.0 1.2
0 16 3 1 1
1 0 3 0 0
0 7 1 0 1
1 5 5 1 0
0 4 0 0 0
0 10 1 0 1
0 3 3 1 0
1 3 2 0 0
1 2 5 0 1
0 14 1 1 0
0 0 0 0 0
1 8 5 1 1
0 8 1 0 0
0 0 0 0 0
Mann, Mannosidosis; ALD, adrenoleukodystrophy; GLD, globoid
ucolipidosis type II; Bu/Cy, busulfan/cyclophosphamide; Cy/TBI,
total body irradiation; CSA, cyclosporin A.(
)
rome;
ell, mzed according to the total protein content of each
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Allogeneic HCT in Patients with Inherited Metabolic Storage Disorders
Bample and analyzed as picograms per gram of total
rotein. Two-sample t tests were used to compare
ifferences between the means of any 2 of the 3 pul-
onary complication groups. Two-sample t tests were
lso used to compare differences in mean cytokine
alues between children with MPS who developed a
ulmonary complication and those with MPS who did
ot develop any pulmonary complication, between all
hildren with MPS and those with leukodystrophy,
nd between children with MPS who had a pulmonary
omplication and children with leukodystrophy who
ad a pulmonary complication. All statistical analyses
ere performed with SAS version 8.02 (SAS Institute,
ary, NC).
ESULTS
ulmonary Complications
The overall incidence of pulmonary complications
n this study of 48 patients with IMSD was 52%
25/48) over a period of 4 years: this included 11
23%) infectious and 14 (29%) noninfectious compli-
ations. Data regarding the various complications are
resented in Table 2. Infectious pulmonary complica-
ions occurred in 6 MPS and 5 non-MPS patients.
hese included pneumonias caused by cytomegalovirus,
espiratory syncytial virus, adenovirus, herpes simplex 1,
arainﬂuenza, Pseudomonas aeruginosa, -hemolytic Strep-
ococcus species, and Candida albicans. Overall, 14 patients
eveloped noninfectious complications, and 12 of
hese had an underlying diagnosis of MPS (10 Hurler
yndrome and 2 Maroteaux-Lamy syndrome), whereas
had non-MPS diagnoses (1 adrenoleukodystrophy and
I-cell disease). The most frequent noninfectious
omplication was DAH (9 patients; 19%), IPS (4 pa-
ients; 8%), pulmonary cytolytic thrombi, and post-
ransplantation lymphoproliferative disease with pri-
ary pulmonary involvement. The combined incidence
able 2. Post-HCT Pulmonary Complications
Pulmonary Complication
MPS
(n  23)
Non-MPS
(n  25)
nfectious (n  11)* 6 5
Viral 4 2
Bacterial 2 0
Fungal 0 4
edian time after HCT, d (range) 101 (7-189) 75 (12-138)
oninfectious (n  14)† 12 2
Diffuse alveolar hemorrhage 9 0
Idiopathic pneumonia syndrome 2 2
Pulmonary cytolytic thrombi 1 0
PTLD 1 0
edian time after HCT, d (range) 62 (7-194) 150 (13-300)
PS indicates mucopolysaccharidoses; PTLD, posttransplantation
lymphoproliferative disease.
One patient had 2 infectious complications.
uOne patient had 2 noninfectious complications.
B&MTf DAH and IPS, the 2 major noninfectious compli-
ations, was 27% (13/48). Although the other nonin-
ectious complications were equally distributed in the
tudy population, DAH occurred exclusively in pa-
ients with MPS (Hurler syndrome, n  7; Maro-
eaux-Lamy, syndrome, n  2).
Patient outcomes are shown in Table 3. The over-
ll mortality in this study sample of 48 IMSD patients
as 42% (20/48), with 25% (5/20) deaths secondary to
ulmonary complications. Four of the 5 deaths from
ulmonary causes were in children with MPS, as op-
osed to only 1 with a non-MPS diagnosis. Overall,
6% of deaths in patients with MPS were from pul-
onary causes.
BAL ﬂuid obtained immediately before transplan-
ation was analyzed for infectious organisms. Five pa-
ients who were clinically asymptomatic had BAL ﬂuid
ultures positive for Pseudomonas aeruginosa (n  2),
treptococcus pneumoniae (n  1), -hemolytic Strep-
ococcus species (n  1), and Branhamella catarrhalis
n  1). These patients were treated with appropriate
ntibiotics before HCT. None of these patients de-
eloped an infectious pulmonary complication after
CT. No pretransplantation viral or fungal cultures
rom BAL ﬂuid were positive.
BAL ﬂuid was analyzed for protein and nitrite
evels. These levels were not different in patients who
eveloped pulmonary complications compared with
atients who had no complications.
ytokine Analysis
Complete cytokine data were available for 35 of 48
atients in the study. This was due to logistic prob-
ems in obtaining the samples given that bronchos-
opy was performed only when patients were sched-
able 3. Patient Outcomes
Outcome
MPS
(n  23)
Non-MPS
(n  25)
live 12 (52%) 16 (64%)
ulmonary causes of death 5 2
DAH 2 0
PTLD with pulmonary involvement 2 0
Pulmonary hypertension 0 1
Respiratory failure 1 1
onpulmonary causes of death 6 7
Sudden cardiac event 1 0
GVHD 1 0
Infection 3 3
Hemolytic anemia 1 1
Disease progression 0 2
HUS/TTP 0 1
AH indicates diffuse alveolar hemorrhage; PTLD, Epstein-Barr
virus posttransplantation lymphoproliferative disease; GVHD,
graft-versus-host disease; HUS/TTP, hemolytic uremic syn-
drome/thrombotic thrombocytopenic purpura; MPS, mucopo-
lysaccharidoses.led to undergo an elective procedure in the operating
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4oom, to prevent unnecessary sedation or anesthesia
isks associated with a bronchoscopy performed only
or research. In 12 patients, BAL specimens could not
e obtained for the this reason, and 1 patient was not
ncluded in the analysis because his follow-up period
as 100 days at the time of analysis. Five of the 35
atients developed infectious complications, 8 had non-
nfectious complications, and the remaining 22 had no
omplications. Levels of various cytokines, including IL-
, IL-2, IL-4, IL-6, IL-8, TNF-, IL-10, and granu-
ocyte colony-stimulating factor (G-CSF), and chemo-
ines, including MCP-1 and MIP-1, were compared
nd are shown in Table 4. Patients who developed
oninfectious pulmonary complications that were ei-
her IPS or DAH were compared with those who had
o pulmonary complications. Patients with IPS or
AH were found to have higher concentrations of
L-1 (P  .03), IL-6 (P  .04), IL-8 (P  .04), and
-CSF (P  .003) when compared with patients who
ad no pulmonary complications after HCT. There
as no difference in the cytokine levels between pa-
ients who developed infectious pulmonary complica-
ions and those who had none (data not shown).
Because DAH was seen exclusively in patients with
PS, concentrations of cytokines and chemokines in
heir pretransplantation BAL ﬂuid were compared in
his group of patients with those who had leukodys-
rophies (Table 5). Patients with MPS had signiﬁ-
antly higher concentrations of IL-1 (P  .03), IL-6
P  .01), IL-8 (P  .02), TNF- (P  .03), G-CSF
P  .005), and MIP-1 (P  .06). However, when
atients with MPS who developed pulmonary compli-
ations were compared with MPS patients who did
ot develop pulmonary complications, no signiﬁcant
ifferences were found in the levels of various cyto-
ines and chemokines tested (Table 6).
able 4. Comparisons of Mean Cytokine and Chemokine
oncentrations in BAL ﬂuid between Patients with Noninfectious
ulmonary Complications (DAH or IPS) and Those with No
ulmonary Complications
Variable
Noninfectious
Pulmonary
Complication
(Mean)*
No
Pulmonary
Complication
(Mean)*
None vs.
Noninfectious
(P Value)
IP-1 152.7 123.3 .37
CP-1 536.4 233.8 .41
L-1 131.0 32.7 .03
L-2 44.79 79.5 .78
L-4 195.6 97.5 .50
L-6 95.47 23.3 .04
L-8 4368.0 2152.5 .04
L-10 0.61 1.6 .77
-CSF 1089.2 285.5 .003
EGF 3879.1 2515.3 .82
NF- 103.0 47.3 .31
EGF indicates vascular endothelial growth factor.
Means are presented as picograms per gram of total protein. *
34ISCUSSION
The pathogenesis of pulmonary complications in
atients undergoing HCT is unclear. Various studies,
oth in mice and humans, suggest that the local proin-
ammatory cytokine cascade generated by the alveolar
acrophages, as well as donor-derived cytokines such
s TNF-, play a key role in the development of these
oninfectious complications after HCT. These cyto-
ines are secreted as a result of interactions of host
lveolar macrophages in the lung tissue and donor-
erived T cells present locally in the lung [32]. In addi-
ion, endothelial cell apoptosis, which occurs in IPS, is
ssociated with increased levels of TNF- in the BAL
uid of mice, and neutralization of TNF- was found to
revent endothelial injury and signiﬁcantly reduced the
everity of lung disease in these animals [33]. Neutral-
zation of TNF- has been shown to decrease lung
njury after experimental allogeneic HCT in other
urine models of IPS as well [34,35]. Shukla et al. [28]
ave shown that mice that are TNF receptor 1 deﬁ-
ient exhibit decreased IPS injury, which was also
ssociated with decreased levels of NO. In addition, 3
atients with IPS who were treated with anti–TNF-
ntibody showed clinical improvement in their lung
isease [36]. Serum levels of proinﬂammatory cyto-
ines such as IL-6, IL-8, and TNF- are increased
able 5. Comparison of Mean Cytokine/Chemokine Levels in MPS
ersus Non-MPS Group
Cytokine/Chemokine
MPS
(Mean)
Non-MPS
(Mean) P Value
L-1 89.52 12.96 .03
L-6 71.78 1.87 .01
L-8 3775.93 1307.49 .02
NF- 106.28 1.11 .03
IP-1 190.78 31.96 .06
-CSF 754.31 162.65 .005
eans are presented as picograms per gram of total protein.
able 6. Comparisons of Mean Cytokine and Chemokine
oncentrations in BAL Fluid between MPS Patients with
nd without Pulmonary Complications
Variable
MPS with
Pulmonary
Complication
MPS without
Pulmonary
Complication
(Mean)* (Mean)* P Value
IP-1 129.6 300.9 .32
CP-1 514.1 275.9 .59
L-1 104.2 69.9 .68
L-2 40.9 31.3 .84
L-4 154.9 6.1 .28
L-6 71.6 72.0 .99
L-8 4327.2 3155.7 .52
L-10 0.48 2.5 .24
-CSF 1022.3 397.0 .16
EGF 3081.9 784.0 .32
NF- 85.1 130.1 .66Means are presented as picograms per gram of total protein.
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Barly after HCT in patients with major transplant-
elated complications, including IPS [37]. Conversely,
igh levels of IL-10 have been associated with fewer
CT-related complications and early deaths, thus
uggesting that IL-10 may play a protective role [38].
In another recent study, production of IL-1,
L-6, IL-8, TNF-, and granulocyte-macrophage col-
ny-stimulating factor (GM-CSF) by the alveolar
acrophages in the BAL ﬂuids of patients undergoing
CT, both before HCT and during the period of
ancytopenia after HCT, was analyzed. This study
ound higher levels of TNF-, GM-CSF, and IL-6 in
atients who developed pulmonary complications af-
er HCT as opposed to those who did not. GM-CSF,
n particular, was believed to play an important role in
aintaining the proinﬂammatory environment after
CT, as evidenced by its higher levels during the
ancytopenic period as well [39].
Additionally, chemokines such as RANTES have
een found to play a contributory role in lung injury
f IPS. Increased levels of RANTES were found to
oincide with increased expression of CCR1 and
CR5, the receptors for RANTES, and the use of
ANTES-deﬁcient donor T cells resulted in a sig-
iﬁcant reduction in lung injury, thereby demon-
trating an important role of this chemokine in the
athophysiology of IPS. Similarly, interactions be-
ween CXCR3, a chemokine receptor, with its li-
ands have been shown to signiﬁcantly contribute
o donor T-cell recruitment to the lung after allo-
CT, and blockade of this interaction has been
hown to reduce the severity of IPS in a murine bone
arrow transplantation model [40].
Donor-derived TNF- is also critical to the de-
elopment of IPS, as was recently shown by Hilde-
randt et al. [41]. These investigators demonstrated
hat allogeneic bone marrow transplantation from
NF-/ donors signiﬁcantly reduced the produc-
ion of key chemokines, including RANTES, mono-
ine induced by interferon , MIP-1, and MCP-1.
hus, proinﬂammatory cytokines and chemokines
lay an important role in the pathogenesis of IPS.
The pathogenesis of DAH, conversely, is not
nown. After HCT, patients with IMSD, especially
hose with Hurler syndrome, have a higher risk of
eveloping DAH. Although there has been no large
eries reported in the literature, small series and case
eports have described post-HCT pulmonary compli-
ations such as DAH and IPS in patients with Hurler
yndrome [17,18,20,42].
This single-center study is the ﬁrst to prospec-
ively evaluate the risk of pulmonary complications in
atients with IMSDs after HCT, as well as to begin to
nvestigate the underlying pathogenesis in this high-
isk group. Our study conﬁrms a high risk of devel-
ping DAH and IPS after HCT in this group of
atients. Although IPS was seen in patients with MPS a
B&MTs well as non-MPS, DAH was seen exclusively in
atients with MPS in our series. DAH developed early
fter HCT and was found to be severe and frequently
ife-threatening; it typically necessitated prolonged
entilatory support. In the general HCT population,
AH is a relatively uncommon complication after
CT, with an incidence of approximately 5% [19,20].
arious risk factors that have been associated with
AH include the pretransplantation conditioning
egimen, autologous transplantation, thoracic radia-
ion, and an older age at HCT [43].
In this study, high local concentrations of proin-
ammatory cytokines, including IL-1, IL-6, IL-8,
nd G-CSF, were found in patients who subsequently
eveloped noninfectious pulmonary complications
ompared with those who did not develop any pulmo-
ary complications after HCT. No signiﬁcant differ-
nces were found with regard to cytokine levels in the
roup that developed infectious pulmonary complica-
ions. Most noninfectious pulmonary complications
eveloped in patients with MPS, including those with
urler and Maroteaux-Lamy syndromes. It is inter-
sting to note that signiﬁcantly higher concentrations
f several proinﬂammatory cytokines were found in
he MPS group compared with the non-MPS group.
owever, within the MPS patients themselves, those
ho developed pulmonary complications after HCT
id not have signiﬁcant differences in the concentra-
ions of these cytokines and chemokines. This ﬁnding
uggests that other factors, in addition to these cyto-
ines and/or other cytokines that were not evaluated
n our study, may promote the development of non-
nfectious pulmonary complications. Other factors
hat may be important, such as conditioning regimen,
LA disparity, and stem cell source, could not be
nalyzed because of small numbers of patients within
he different groups. In addition, our study did not
nclude analysis of donor TNF- levels, which in
ome very recent animal experiments have been found
o play an important role in initiating pulmonary che-
okine response and, ultimately, lung injury, as seen
n IPS [41]. Understanding the pathophysiology of
ulmonary complications in patients with IMSDs has
linical implications in terms of treatment options or
ven preventive strategies based on their cytokine and
hemokine proﬁles. Corticosteroids have been tradi-
ionally used for the treatment of DAH, but whether
heir use would be beneﬁcial in preventing the devel-
pment of DAH by suppressing the inﬂammatory
esponse in patients with Hurler syndrome is not
lear.
In conclusion, patients with IMSDs are at a high
isk of developing pulmonary complications after
CT. Of the IMSD patients, patients with MPS,
ncluding Hurler and Maroteaux-Lamy syndromes,
re at a signiﬁcantly higher risk of developing DAH
fter HCT than patients with other metabolic disor-
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4ers. Patients with MPS have higher concentrations of
roinﬂammatory cytokines in the BAL ﬂuid before
CT, which could be related to the deposition of
lycosaminoglycans in the lung tissue, and this, in
ombination with other factors, may predispose them
o the development of noninfectious pulmonary com-
lications, particularly DAH, in the early period after
CT. Further studies of larger numbers of MPS
atients and, potentially, other cytokines or chemo-
ines will be necessary to further investigate this ob-
ervation.
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